Taiyen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,349	1,551	1,445	1,529	1,726
Short-Term Investments	11.41	40.31	4.24	-	1.06
Trading Asset Securities	384.99	346.32	390.61	353.18	353.54
Cash & Short-Term Investments	1,746	1,938	1,840	1,882	2,080
Cash Growth	-9.92%	5.35%	-2.27%	-9.52%	10.15%
Accounts Receivable	524.03	498.3	663.23	650.28	757.6
Other Receivables	9.68	6.23	23.43	32.78	7.19
Receivables	533.71	504.53	686.66	683.06	764.79
Inventory	376.81	427.32	394.74	407.37	395.02
Other Current Assets	99.94	57.64	105.27	121.26	154.52
Total Current Assets	2,756	2,927	3,026	3,094	3,395
Property, Plant & Equipment	4,119	4,023	3,905	3,713	3,564
Long-Term Investments	40.98	40.97	33.96	-	-
Other Intangible Assets	10.17	11.71	6.41	5.34	8.53
Long-Term Deferred Tax Assets	57.03	63.65	81.9	72.12	87.22
Other Long-Term Assets	1,279	1,315	1,266	1,327	1,413
Total Assets	8,263	8,381	8,320	8,212	8,468
Accounts Payable	329.32	419.51	384.5	399.06	485.3
Short-Term Debt	86	98	100	20	287.53
Current Portion of Long-Term Debt	5.56	66.95	15.31	8.65	4.29
Current Portion of Leases	7.41	8.76	7.26	9.27	10.76
Current Income Taxes Payable	52.02	43.36	66.29	42.17	79.75
Current Unearned Revenue	70.19	109.76	98.03	102.23	79.02
Other Current Liabilities	409.4	418.81	429.62	344.67	358.74
Total Current Liabilities	959.89	1,165	1,101	926.05	1,305
Long-Term Debt	-	5.56	72.5	68.93	53.08
Long-Term Leases	26.56	25.93	25.09	28.59	36.33
Long-Term Unearned Revenue	284.66	297.72	307.19	320.05	332.92
Pension & Post-Retirement Benefits	3.17	37.68	94.04	62.39	108.81
Long-Term Deferred Tax Liabilities	35.3	39.44	34.38	34.23	34.08
Other Long-Term Liabilities	139.22	142.08	136.68	109.52	83.67
Total Liabilities	1,449	1,714	1,771	1,550	1,954
Common Stock	2,000	2,000	2,000	2,000	2,000
Additional Paid-In Capital	2,491	2,502	2,502	2,502	2,502
Retained Earnings	2,325	2,165	1,993	2,022	1,862
Comprehensive Income & Other	-2.39	-2.63	-3.38	-2.99	-2.16
Total Common Equity	6,814	6,664	6,491	6,521	6,361
Minority Interest	-	3.53	57.6	140.69	152.2
Shareholders' Equity	6,814	6,668	6,549	6,662	6,513
Total Liabilities & Equity	8,263	8,381	8,320	8,212	8,468
Total Debt	125.52	205.2	220.17	135.44	391.98
Net Cash (Debt)	1,620	1,733	1,619	1,747	1,688
Net Cash Growth	-6.49%	7.00%	-7.29%	3.46%	0.42%
Net Cash Per Share	8.07	8.64	8.08	8.71	8.42
Filing Date Shares Outstanding	200	200	200	200	200
Total Common Shares Outstanding	200	200	200	200	200
Working Capital	1,796	1,762	1,925	2,168	2,089
Book Value Per Share	34.07	33.32	32.46	32.61	31.81
Tangible Book Value	6,804	6,652	6,485	6,516	6,353
Tangible Book Value Per Share	34.02	33.26	32.42	32.58	31.76
Land	1,816	1,816	1,816	1,816	1,736
Buildings	1,654	1,568	1,423	1,354	1,322
Machinery	3,640	3,507	3,004	2,837	2,844
Construction In Progress	79.36	186.56	632.49	440.46	323.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.